The Trinity – Balance of Safety, Efficacy, and Quality of Life in TCR RRMM treatment
Friday 16th May 2025 | 07:30–08:15 CEST
Chair
Associate Professor
María Victoria Mateos, PhD
Associate Professor of Medicine, and Director of the Myeloma Program at the University of Salamanca, Spain
Speaker
Dr. Manfred Welslau, PhD
Head of the Department of Oncology at Klinikum Aschaffenburg-Alzenau in Germany
Speaker
Adjunct Professor
Claudio Cerchione, PhD
Adjunct Professor at Hematology Unit – Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST IRCCS, Meldola (FC) Italy – Director of Myeloma Clinical and Research Group in the Comprehensive Cancer Care and Research Network of Romagna
| AGENDA |
|---|
| Current treatment challenges: Unmet need in a vulnerable patient group |
| Introducing a new way of evaluating treatment for MM patients: The Trinity |
| Melflufen data insights for TCR RRMM: Safety, Efficacy and QoL |
| Panel discussion: Real-world patient cases |
MED-ALL—2500010 April 2025
